Investor News


Hørsholm, Denmark, February 9, 2012



Veloxis Pharmaceuticals to Present at 14th Annual BIO CEO & Investor
Conference

William J. Polvino M.D president and CEO of Veloxis Pharmaceuticals A/S, will
present at the 14th Annual BIO CEO & Investor Conference at 3 p.m. EST,
Tuesday, Feb. 14, at The Waldorf-Astoria in New York. Dr. Polvino will present
an overview of the company and discuss top-line Phase 3 results of LCP-Tacro™,
Veloxis’ candidate to prevent organ transplant rejection.

About Veloxis Pharmaceuticals A/S

Based in Hørsholm, Denmark, with an office in New Jersey, Veloxis
Pharmaceuticals A/S, or Veloxis, is a specialty pharmaceutical company.
Clinical development is the core of Veloxis’ efforts to develop a product
portfolio which includes the Company’s lead product candidate, LCP‐Tacro™, for
immunosuppression, specifically organ transplantation, and products to combat
certain cardiovascular diseases. Veloxis adapts new technologies on a fast
commercial timetable. Veloxis’ unique, patented delivery technology, MeltDose®,
can improve absorption and bioavailability ‐ at low‐scale up costs ‐ not only
for a broad spectrum of drugs already on the market but also for new chemical
entities. Veloxis has a lipid lowering product, Fenoglide®, currently on the
U.S. market and a diversified near and medium term pipeline with three clinical
stage product candidates and a number of projects in preclinical development.

For further information, please visit www.veloxis.com.


For U.S. investor and media contacts:

John Weinberg, M.D., Senior VP, Commercial Operations and Investor Relations

Veloxis Pharmaceuticals A/S

(732) 321-3208

[email protected]

090212 Investor News BIO CEO & Investor Conference.pdf